anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

224,701-224,760 of 319,975

filter-aware
04
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · Evidence1 hit
05
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · Evidence1 hit
06
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · Evidence1 hit
07
The chart uses a stacked bar format to show both total revenue growth and the changing composition of product contributions over time.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · Evidence1 hit
08
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · EvidenceLoop · Voice Of Customer1 hit
09
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · EvidenceLoop · Voice Of Customer1 hit
10
The slide uses a structured layout to present clinical outcomes alongside a study overview box.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · EvidenceLoop · Voice Of Customer1 hit
11
Includes product branding and dosing regimen details.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · EvidenceLoop · Voice Of Customer1 hit
12
The chart shows a steady increase in annual net sales for VIVITROL.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · EvidenceLoop · Voice Of Customer1 hit
13
Includes disclaimer regarding patent litigation and definition of R12M.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · EvidenceLoop · Voice Of Customer1 hit
14
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations 1 hit
15
The slide uses a process flow diagram to illustrate the drug development lifecycle capabilities.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations 1 hit
16
Includes a medical illustration of brain pathways related to wakefulness and neurotransmitters.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
17
The chart is currently empty, serving as a framework template for future data plotting.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
18
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
19
The radar chart represents a multi-dimensional optimization framework for drug development.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
20
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
21
The slide features a screenshot of a conference poster or presentation title slide.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
22
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
23
The slide outlines a standard clinical trial protocol structure.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
24
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
25
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
26
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · Resolution1 hit
27
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · Resolution1 hit
28
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · Resolution1 hit
29
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · Resolution1 hit
01
Slide 1
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
02
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
03
The slide uses a simple icon-based visual to anchor the core strategic goal.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
04
The slide uses a structured grid layout to present high-level value propositions.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style visualization to represent drug development stages.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
07
The slide uses a map to show regional prevalence and a nested circle diagram to show the funnel from total infected to treated patients.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a process-oriented flow diagram to explain the therapeutic strategy.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
The slide highlights the mechanism of action and key benefits of the drug candidate.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
11
Data presented at EASL 2022, AASLD 2022, GHS 2023.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
12
Data presented at EASL 2022. Shows dual-axis line charts for viral load/ALT and bar charts for T-cell frequency.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
13
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
14
The slide outlines a clinical trial protocol with specific patient counts (n=12, n=8) and timeline milestones (weeks 1, 24, 28, 40, 52).Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
15
Data presented at EASL 2023. Includes both a summary table of mean changes and individual patient trajectory charts.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
16
Shows two parallel study arms with randomization at week 24/26.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
17
Data presented at AASLD 2023; includes both a summary table and a longitudinal line chart with error bars.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
18
Data presented at AASLD 2023. Shows ELISpot results for T cell responses and HBsAg levels.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
The slide details a specific licensing deal with Qilu Pharmaceutical, including financial terms and geographic scope.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
20
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
21
The slide uses a three-column layout to explain the scientific basis and product advantages.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
22
Includes both in vitro (IFN-y fold increase) and in vivo (MC38 tumor model) efficacy data.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
23
The slide outlines a multi-part clinical trial structure with specific cohort sizes and dosing progression.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
24
Includes a footnote regarding the 3/21/2023 Court Scheduling Order.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
25
The slide includes a financial disclaimer regarding cash balance and burn.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
26
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
01
Slide 1
argenx SE | Investor Conference Presentation Deck | 27 slidesargenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Humble Origins1 hit
02
argenx SE | Investor Conference Presentation Deck | 27 slidesargenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Humble Origins1 hit
03
The infinity loop suggests a continuous, self-reinforcing process of innovation.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Humble Origins1 hit
04
The slide uses a large portrait of a patient to build emotional connection and credibility.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Early Struggles1 hit
05
Uses a concentric circle/horizon layout to represent different stages of development and commercialization.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Early StrugglesLoop · Why Now1 hit
06
The slide uses a circular/concentric layout to represent the 'horizon' of opportunities, with the pipeline on the left and commercial/development milestones on the right.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Early StrugglesLoop · Why Now1 hit
07
The slide uses an infinity-loop style diagram to connect three pillars of leadership.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
08
The slide highlights clinical outcomes (QoL, MG-ADL scores), treatment protocols (steroid tapering), patient support (My VYVGART Path), and economic value (cost/benefit vs IVIg).argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit